{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:13:59Z","timestamp":1791335639083,"version":"4.3.1"},"reference-count":99,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T00:00:00Z","timestamp":1581984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1107043"],"award-info":[{"award-number":["APP1107043"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR2016"],"award-info":[{"award-number":["ANR2016"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.00126","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T05:36:08Z","timestamp":1582004168000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":37,"title":["Antiangiogeneic Strategies in Mesothelioma"],"prefix":"10.3389","volume":"10","author":[{"given":"Anna K.","family":"Nowak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solenn","family":"Brosseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Zalcman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,2,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","article-title":"Malignant mesothelioma","volume":"366","author":"Robinson","year":"2005","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.athoracsur.2017.09.036","article-title":"National trends in the epidemiology of malignant pleural mesothelioma: a national cancer data base study","volume":"105","author":"Saddoughi","year":"2018","journal-title":"Ann Thorac Surg."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","article-title":"Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada","volume":"23","author":"van Meerbeeck","year":"2005","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1200\/JCO.2012.46.3653","article-title":"Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers","volume":"31","author":"Jain","year":"2013","journal-title":"J Clin Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1128\/MCB.24.7.2875-2889.2004","article-title":"Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance","volume":"24","author":"Erler","year":"2004","journal-title":"Mol Cell Biol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/j.1582-4934.2010.01016.x","article-title":"Oxygen-mediated endocytosis in cancer","volume":"14","author":"Wang","year":"2010","journal-title":"J Cell Mol Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1158\/0008-5472.CAN-10-4049","article-title":"Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer","volume":"71","author":"Chang","year":"2011","journal-title":"Cancer Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1535-6108(03)00085-0","article-title":"Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene","volume":"3","author":"Pennacchietti","year":"2003","journal-title":"Cancer Cell."},{"key":"B11","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell."},{"key":"B12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.lungcan.2005.07.010","article-title":"Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM)","volume":"51","author":"Klabatsa","year":"2006","journal-title":"Lung Cancer."},{"key":"B13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1046\/j.1365-2559.2001.01211.x","article-title":"Endothelial nitric oxide synthase is strongly expressed in malignant mesothelioma but does not associate with vascular density or the expression of VEGF, FLK1 or FLT1","volume":"39","author":"Soini","year":"2001","journal-title":"Histopathology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/sj.bjc.6690650","article-title":"VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours","volume":"81","author":"Ohta","year":"1999","journal-title":"Br J Cancer."},{"key":"B15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s004280050388","article-title":"Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma","volume":"435","author":"Konig","year":"1999","journal-title":"Virchows Arch."},{"key":"B16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000029460","article-title":"Co-expression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesothelioma","volume":"67","author":"Konig","year":"2000","journal-title":"Respiration."},{"key":"B17","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/ijc.10996","article-title":"Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops","volume":"104","author":"Masood","year":"2003","journal-title":"Int J Cancer."},{"key":"B18","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/path.824","article-title":"Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma","volume":"193","author":"Strizzi","year":"2001","journal-title":"J Pathol."},{"key":"B19","first-page":"5590","article-title":"Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up-regulation of vascular endothelial growth factor expression","volume":"57","author":"Deroanne","year":"1997","journal-title":"Cancer Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S1040-8428(00)00062-7","article-title":"Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis","volume":"34","author":"Gerwins","year":"2000","journal-title":"Crit Rev Oncol Hematol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0","article-title":"Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and\u22122, and TGF beta expression","volume":"189","author":"Kumar-Singh","year":"1999","journal-title":"J Pathol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1158\/1078-0432.CCR-04-2109","article-title":"Up-regulation of EphB4 in mesothelioma and its biological significance","volume":"11","author":"Xia","year":"2005","journal-title":"Clin Cancer Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"21S","DOI":"10.1378\/chest.109.3_Supplement.21S","article-title":"Angiogenesis in mesotheliomas. Role of mesothelial cell derived IL-8","volume":"109","author":"Antony","year":"1996","journal-title":"Chest."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2570::AID-CNCR12>3.0.CO;2-F","article-title":"Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma","volume":"85","author":"Ohta","year":"1999","journal-title":"Cancer."},{"key":"B25","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2174\/187153006778250028","article-title":"Drug targets to pro-angiogenetic factors with special reference to primary peritoneal mesothelioma","volume":"6","author":"Ranieri","year":"2006","journal-title":"Endocr Metab Immune Disord Drug Targets."},{"key":"B26","first-page":"4593","article-title":"Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders","volume":"57","author":"Presta","year":"1997","journal-title":"Cancer Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"14765","DOI":"10.1073\/pnas.93.25.14765","article-title":"Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor\/vascular permeability factor antibody","volume":"93","author":"Yuan","year":"1996","journal-title":"Proc Natl Acad Sci USA."},{"key":"B28","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1158\/0008-5472.671.65.3","article-title":"Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies","volume":"65","author":"Gerber","year":"2005","journal-title":"Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1172\/JCI117857","article-title":"Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis","volume":"95","author":"Warren","year":"1995","journal-title":"J Clin Invest."},{"key":"B30","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/S0022-5347(01)61829-9","article-title":"Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model","volume":"161","author":"Melnyk","year":"1999","journal-title":"J Urol."},{"key":"B31","first-page":"488","article-title":"The effect of antibody to vascular endothelial growth factor and cisplatin on the growth of lung tumors in nude mice","volume":"36","author":"Kabbinavar","year":"1995","journal-title":"Proc Am Assoc Cancer Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.mvr.2007.05.003","article-title":"Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization","volume":"74","author":"Fukumura","year":"2007","journal-title":"Microvasc Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"5918","DOI":"10.1158\/1078-0432.CCR-07-0501","article-title":"The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice","volume":"13","author":"Li","year":"2007","journal-title":"Clin Cancer Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1200\/JCO.2001.19.3.851","article-title":"Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety","volume":"19","author":"Margolin","year":"2001","journal-title":"J Clin Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00228-010-0988-x","article-title":"Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials","volume":"67","author":"Hang","year":"2011","journal-title":"Eur J Clin Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e4232","DOI":"10.1097\/MD.0000000000004232","article-title":"Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: an updated meta-analysis of 12 randomized controlled trials","volume":"95","author":"Zhu","year":"2016","journal-title":"Medicine."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1007\/s00280-013-2155-4","article-title":"Bevacizumab and central nervous system (CNS) hemorrhage","volume":"71","author":"Letarte","year":"2013","journal-title":"Cancer Chemother Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000314980","article-title":"Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis","volume":"79","author":"Hapani","year":"2010","journal-title":"Oncology."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappaticci","year":"2007","journal-title":"J Natl Cancer Inst."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.2010.32.3220","article-title":"Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies","volume":"29","author":"Hurwitz","year":"2011","journal-title":"J Clin Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis","volume":"49","author":"Zhu","year":"2007","journal-title":"Am J Kidney Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3816\/CBC.2010.n.016","article-title":"Integrating bevacizumab into the treatment of patients with early-stage breast cancer: focus on cardiac safety","volume":"10","author":"Yardley","year":"2010","journal-title":"Clin Breast Cancer."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1681\/ASN.2010020167","article-title":"Bevacizumab increases risk for severe proteinuria in cancer patients","volume":"21","author":"Wu","year":"2010","journal-title":"J Am Soc Nephrol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1172\/JCI6740","article-title":"VEGF(165) mediates glomerular endothelial repair","volume":"104","author":"Ostendorf","year":"1999","journal-title":"J Clin Invest."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1097\/CAD.0b013e328349c7bb","article-title":"Wound healing and catheter thrombosis after implantable venous access device placement in 266 breast cancers treated with bevacizumab therapy","volume":"22","author":"Kriegel","year":"2011","journal-title":"Anticancer Drugs."},{"key":"B46","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/jso.20301","article-title":"Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab","volume":"91","author":"Scappaticci","year":"2005","journal-title":"J Surg Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.ejca.2012.02.052","article-title":"Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study","volume":"48","author":"Kabbinavar","year":"2012","journal-title":"Eur J Cancer."},{"key":"B48","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/cncr.23617","article-title":"Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma","volume":"113","author":"Jackman","year":"2008","journal-title":"Cancer."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","article-title":"Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma","volume":"30","author":"Kindler","year":"2012","journal-title":"J Clin Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/bjc.2013.368","article-title":"Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma","volume":"109","author":"Ceresoli","year":"2013","journal-title":"Br J Cancer."},{"key":"B51","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.lungcan.2012.05.111","article-title":"A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma","volume":"77","author":"Dowell","year":"2012","journal-title":"Lung cancer."},{"key":"B52","doi-asserted-by":"publisher","first-page":"5759","DOI":"10.1158\/1078-0432.CCR-18-2860","article-title":"Health-realted quality of life impact from adding bevacizumab to cisplatin-pemetrexed in malignant pleural mesothelioma in the MAPS IFCT-GFPC-0701 phase III trial","volume":"25","author":"Eberst","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B53","first-page":"341","article-title":"SU5416 in malignant mesothelioma: a University of Chicago phase II consortium study","volume":"20","author":"Kindler","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2006.24.18_suppl.7081","article-title":"Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): a phase II study by the Cancer and Leukemia Group B (CALGB 30107)","volume":"24","author":"Jahan","year":"2006","journal-title":"J Clin Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.lungcan.2004.10.005","article-title":"Thalidomide in patients with malignant pleural mesothelioma","volume":"48","author":"Baasa","year":"2005","journal-title":"Lung Cancer"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1200\/JCO.2009.27.3649","article-title":"Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma","volume":"28","author":"Gregorc","year":"2010","journal-title":"J Clin Oncol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1097\/JTO.0b013e31825f22ee","article-title":"A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma","volume":"7","author":"Nowak","year":"2012","journal-title":"J Thorac Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1097\/JTO.0b013e3181ec18db","article-title":"A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307","volume":"5","author":"Dubey","year":"2010","journal-title":"J Thorac Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1097\/JTO.0b013e318229586e","article-title":"Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509","volume":"6","author":"Garland","year":"2011","journal-title":"J Thorac Oncol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1097\/JTO.0b013e3182333df5","article-title":"Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. The NCIC Clinical Trials Group","volume":"6","author":"Laurie","year":"2011","journal-title":"J Thorac Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.lungcan.2012.06.011","article-title":"Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium","volume":"78","author":"Campbell","year":"2012","journal-title":"Lung Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.lungcan.2013.05.006","article-title":"A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma","volume":"81","author":"Nowak","year":"2013","journal-title":"Lung Cancer."},{"key":"B63","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/JTO.0b013e31828c2b26","article-title":"Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy","volume":"8","author":"Papa","year":"2013","journal-title":"J Thorac Oncol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S1470-2045(13)70125-6","article-title":"Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study","volume":"14","author":"Buikhuisen","year":"2013","journal-title":"Lancet Oncol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/S1470-2045(18)30193-1","article-title":"NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"19","author":"Gregorc","year":"2018","journal-title":"Lancet Oncol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.lungcan.2011.11.014","article-title":"Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107)","volume":"76","author":"Jahan","year":"2012","journal-title":"Lung Cancer."},{"key":"B67","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/S0169-5002(03)91684-9","article-title":"Thalidomide alone or in combination with cisplatin\/Gemcitabine in malignant pleural mesothelioma (MM); Interim results from two parallel non randomized phase II studies","volume":"41","author":"Pavlakis","year":"2003","journal-title":"Lung Cancer"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.jtho.2017.05.021","article-title":"Phase I Trial of Cediranib in combination with cisplatin and pemetrexed in chemo naive patients with unresectable malignant pleural mesothelioma (SWOG S0905)","volume":"12","author":"Tsao","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1200\/JCO.2017.72.9012","article-title":"Nintedanib plus pemetrexed\/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-meso trial","volume":"35","author":"Grosso","year":"2017","journal-title":"J Clin Oncol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1200\/JCO.19.00269","article-title":"Phase II trial of cediranib in combination with cisplatin and pemetrexed in chemotherapy-naive patients with unresectable malignant pleural mesothelioma (SWOG S0905)","volume":"37","author":"Tsao","year":"2019","journal-title":"J Clin Oncol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S2213-2600(19)30139-0","article-title":"Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"7","author":"Scagliotti","year":"2019","journal-title":"Lancet Respir Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1021\/jm501562a","article-title":"Nintedanib: from discovery to the clinic","volume":"58","author":"Roth","year":"2015","journal-title":"J Med Chem."},{"key":"B73","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","article-title":"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial","volume":"15","author":"Reck","year":"2014","journal-title":"Lancet Oncol."},{"key":"B74","article-title":"Preclinical investigation of the therapeutic potential of nintedanib in malignant pleural mesothelioma","volume-title":"13th International Mesothelioma Interest Group","author":"Laszlo","year":"2016"},{"key":"B75","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.cllc.2017.03.010","article-title":"LUME-meso: design and rationale of the phase III part of a placebo-controlled study of nintedanib and pemetrexed\/cisplatin followed by maintenance nintedanib in patients with unresectable malignant pleural mesothelioma","volume":"18","author":"Scagliotti","year":"2017","journal-title":"Clin Lung Cancer."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/81183","article-title":"Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)","volume":"18","author":"Curnis","year":"2000","journal-title":"Nat Biotechnol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(08)60727-8","article-title":"Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial","volume":"371","author":"Muers","year":"2008","journal-title":"Lancet."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.jtho.2016.03.015","article-title":"International experts panel meeting of the Italian Association of Thoracic Oncology on antiangiogenetic drugs for non-small cell lung cancer: realities and hopes","volume":"11","author":"de Marinis","year":"2016","journal-title":"J Thorac Oncol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"S1884","DOI":"10.1016\/j.jtho.2017.09.636","article-title":"Nintedanib + pemetrexed\/cisplatin in malignant pleural mesothelioma (MPM): phase II biomarker data from the LUME-meso study","volume":"12","author":"Nowak","year":"2017","journal-title":"J Thorac Oncol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","article-title":"BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy","volume":"68","author":"Hilberg","year":"2008","journal-title":"Cancer Res."},{"key":"B81","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.lungcan.2016.03.013","article-title":"Nintedanib (BIBF 1120) blocks the tumor promoting signals of lung fibroblast soluble microenvironment","volume":"96","author":"Epstein Shochet","year":"2016","journal-title":"Lung Cancer."},{"key":"B82","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1158\/1535-7163.MCT-12-0995","article-title":"BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer","volume":"12","author":"Kutluk Cenik","year":"2013","journal-title":"Mol Cancer Ther."},{"key":"B83","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1124\/jpet.117.244129","article-title":"Triple angiokinase inhibitor nintedanib directly inhibits tumor cell growth and induces tumor shrinkage via blocking oncogenic receptor tyrosine kinases","volume":"364","author":"Hilberg","year":"2018","journal-title":"J Pharmacol Exp Ther."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of malignant pleural mesothelioma: american society of clinical oncology clinical practice guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J Clin Oncol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1200\/JOP.17.00012","article-title":"Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline summary","volume":"14","author":"Kindler","year":"2018","journal-title":"J Oncol Pract."},{"key":"B86","doi-asserted-by":"publisher","first-page":"825","DOI":"10.6004\/jnccn.2016.0087","article-title":"NCCN guidelines insights: malignant pleural mesothelioma, version 3.2016","volume":"14","author":"Ettinger","year":"2016","journal-title":"J Natl Compr Canc Netw."},{"key":"B87","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.lungcan.2015.05.020","article-title":"Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.S","volume":"89","author":"Kumar","year":"2015","journal-title":"Lung Cancer."},{"key":"B88","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2147\/CEOR.S27770","article-title":"Economic evaluation of bevacizumab in the treatment of nonsmall cell lung cancer (NSCLC)","volume":"4","author":"Chien","year":"2012","journal-title":"Clinicoecon Outcomes Res."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vhri.2018.05.001","article-title":"A trial-based cost-effectiveness analysis of bevacizumab and chemotherapy versus chemotherapy alone for advanced nonsquamous non-small-cell lung cancer in China","volume":"18","author":"Li","year":"2019","journal-title":"Value Health Reg Issues."},{"key":"B90","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s12094-017-1715-1","article-title":"Cost-effectiveness analysis of the addition of bevacizumab to chemotherapy as induction and maintenance therapy for metastatic non-squamous non-small-cell lung cancer","volume":"20","author":"Zheng","year":"2018","journal-title":"Clin Transl Oncol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1743-7563.2011.01399.x","article-title":"Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan","volume":"7","author":"Ahn","year":"2011","journal-title":"Asia Pac J Clin Oncol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/S0169-5002(10)70133-1","article-title":"Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy","volume":"69","author":"Giuliani","year":"2010","journal-title":"Lung Cancer."},{"key":"B93","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1016\/j.ejca.2007.08.017","article-title":"The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales","volume":"43","author":"Tappenden","year":"2007","journal-title":"Eur J Cancer."},{"key":"B94","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1002\/cncr.32368","article-title":"First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: a United States-based cost-effectiveness analysis","volume":"125","author":"Wan","year":"2019","journal-title":"Cancer"},{"key":"B95","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat Rev Immunol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"710","DOI":"10.12688\/f1000research.10795.1","article-title":"Harnessing the immune response to target tumors","volume":"6","author":"Manning","year":"2017","journal-title":"F1000Res."},{"key":"B97","doi-asserted-by":"publisher","first-page":"6171","DOI":"10.1158\/0008-5472.CAN-10-0153","article-title":"Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer","volume":"70","author":"Shrimali","year":"2010","journal-title":"Cancer Res."},{"key":"B98","doi-asserted-by":"publisher","first-page":"346","DOI":"10.4049\/jimmunol.181.1.346","article-title":"Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma","volume":"181","author":"Kusmartsev","year":"2008","journal-title":"J Immunol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1158\/1535-7163.MCT-09-0280","article-title":"Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts","volume":"8","author":"Roland","year":"2009","journal-title":"Mol Cancer Ther."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00126\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T20:31:37Z","timestamp":1665865897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00126\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,18]]},"references-count":99,"alternative-id":["10.3389\/fonc.2020.00126"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.00126","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,18]]},"article-number":"126"}}